$OXFD News
Last published 5y ago
- 5y agoOXFDPKIOxford Immunotec Submits Emergency Use Authorization Request to the FDA and CE Marks T-SPOT®.COVID, a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 InfectionPR NewswireOxford Immunotec Global PLC (Nasdaq: OXFD) (the "Company"), a global, high-growth diagnostics company, announced that today it has released the...
- 5y agoOXFDOxford Immunotec Enters a Memorandum of Understanding (MOU) with GC MS (Green Cross Medical Science Corp. – South Korea) to Market the T-SPOT® Discovery SARS-CoV-2 Kit, for the Measurement of the T Cell Immune Response to SARS-CoV-2 Infection, in South KoreaGlobeNewswireOXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company today...
- 5y agoOXFDOxford Immunotec Updates Their T-SPOT® Discovery SARS-CoV-2 Kit and Include a New Panel to Detect T Cells Reactive to Endemic CoronavirusesGlobeNewswireOXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today...
- 5y agoPROSJWSOXFDCIICMoore Kuehn Encourages PROS, JWS, OXFD, and CIIC Investors to Contact Law FirmPR NewswireMoore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
- 5y agoOXFDNew Monthly Series Spotlights What 100 Physicians Find to be Critical Needs in Their Battle Against COVID-19GlobeNewswireOXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, announces the...
- 5y agoOXFDOxford Immunotec’s T-SPOT® Discovery SARS-CoV-2 Test is Used to Measure the Efficacy of Valneva’s VLA2001 COVID-19 Vaccine Candidate in a Phase I/II Clinical StudyGlobeNewswireOXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, announce the...
- 5y agoOXFDOxford Immunotec Announces the Foundation of the Global T Cell Expert Consortium, Whose First Meeting Took Place This WeekGlobeNewswireOXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, announce the...
- 5y agoOXFDOxford Immunotec Announces the Approval of the T-Cell Select™ Reagent Kit, Used to Automate the T-SPOT®.TB Test Workflow, for IVD Use in South KoreaGlobeNewswireOXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company today announced...
- 5y agoOXFDOxford Immunotec Signs Exclusive Distributor Agreement with RIKEN Genesis, a Subsidiary of Sysmex, to Market the T-SPOT® Discovery SARS-CoV-2 Kit for the Measurement of the T cell Immune Response to SARS-CoV-2 Infection in JapanGlobeNewswireOXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company today announces...
- 5y agoOXFDOxford Immunotec to Hold a Virtual Investor Event on December 17, 2020GlobeNewswireOXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced...
- 6y agoOXFDData Showing SARS-CoV-2 Reactive T Cells are Associated with Protection from COVID-19 – and Can Be Both Detected and Measured Using Oxford Immunotec’s T-SPOT® Technology – is Published by Public Health England and Oxford ImmunotecGlobeNewswireOXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today...
- 6y agoOXFDOxford Immunotec Files Submission to Food and Drug Administration (FDA) for the T-Cell Select™ Reagent KitGlobeNewswireIf approved, the T-Cell Select reagent kit would enable automated sample preparation and the T-SPOT®.TB test to be used with blood samples stored for up to 54 hours at room temperature OXFORD, United...
- 6y agoOXFDOxford Immunotec Global PLC (OXFD) CEO Peter Wrighton-Smith on Q3 2020 Results - Quick Version Earnings Call TranscriptEarnings Call Transcripts
- 6y agoOXFDOxford Immunotec Reports Third Quarter 2020 Financial ResultsGlobeNewswireThird quarter revenue of $19.4 million, above guidance of range of $18 - $19 million Asia-Pacific region returns to growth and sets a new quarterly sales record for the regionEurope & rest of...
- 6y agoOXFDUK Vaccines Taskforce has Selected Oxford Immunotec as the Sole Supplier of T cell Testing for SARS-CoV-2 Specific Responses in New COVID Vaccine TrialsGlobeNewswireOXFORD, United Kingdom and MARLBOROUGH, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today...
- 6y agoOXFDOxford Immunotec Schedules Third Quarter 2020 Earnings Release and Conference Call for November 3, 2020GlobeNewswireOXFORD, United Kingdom and MARLBOROUGH, Mass., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced...
- 6y agoOXFDOxford Immunotec Announces Food and Drug Administration (FDA) Clearance of the T-SPOT®.TB Test for Use in Pediatrics Over the Age of TwoGlobeNewswireOXFORD, United Kingdom and MARLBOROUGH, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the “Company”), a global, high-growth diagnostics company, today...
- 6y agoOXFDOxford Immunotec Joins Forces with Public Health England (PHE) in a Large Clinical Trial Utilizing T-SPOT® Discovery™ SARS-CoV-2 TestGlobeNewswireOXFORD, United Kingdom and MARLBOROUGH, Mass., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today...
- 6y agoOXFDOxford Immunotec Reports Second Quarter 2020 Financial ResultsGlobeNewswireSecond quarter revenue of $5.8 million, a decrease of 70% compared to prior year period, due to the impact of COVID-19 Ended the quarter with approximately $165 million of cash and cash equivalents...
- 6y agoOXFDOxford Immunotec Schedules Second Quarter 2020 Earnings Release and Conference Call for August 4, 2020GlobeNewswireOXFORD, United Kingdom and MARLBOROUGH, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced...
- 6y agoOXFDOxford Immunotec Announces Agreement with Stop TB Partnership - Global Drug Facility (GDF) to Provide Access to the T-SPOT®.TB Test for 100+ TB Burden CountriesGlobeNewswireOXFORD, United Kingdom and MARLBOROUGH, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), today announced that it has entered into a long-term...
- 6y agoOXFDOxford Immunotec releases the T-SPOT® Discovery™ SARS-CoV-2 kit for research into measuring the T cell immune response to SARS-CoV-2, which may offer new insights into immunity to COVID-19GlobeNewswireOXFORD, United Kingdom and MARLBOROUGH, Mass., May 19, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today announces...
- 6y agoOXFDOxford Immunotec Schedules First Quarter 2020 Earnings Release and Conference Call for May 5, 2020GlobeNewswireOXFORD, United Kingdom and MARLBOROUGH, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today...
- 6y agoOXFDOxford Immunotec announces successful re-registration of the T-SPOT®.TB test in ChinaGlobeNewswireOXFORD, United Kingdom and MARLBOROUGH, Mass., April 21, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, high-growth diagnostics company, today announced...
- 6y agoOXFDOxford Immunotec Global PLC's (OXFD) CEO Peter Wrighton-Smith on Q4 2019 Results - Earnings Call TranscriptEarnings Call Transcripts
- 6y agoOXFDOxford Immunotec Reports Fourth Quarter and Full Year 2019 Financial ResultsGlobeNewswireFourth quarter 2019 revenue of $18.1 million, an increase of 18% compared to the prior year periodFourth quarter 2019 gross margin of 78.3%, an increase of 410 basis points from the prior year...
- 6y agoOXFDOxford Immunotec to Present at the Cowen and Company 40th Annual Health Care ConferenceGlobeNewswireOXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, high-growth diagnostics company, today announced that...
- 6y agoOXFDOxford Immunotec Schedules Fourth Quarter and Full Year 2019 Earnings Release and Conference Call for March 2, 2020GlobeNewswireOXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced...
- 6y agoOXFDOxford Immunotec Announces New Data on the Utility of T-SPOT®.CMV in Kidney and Stem Cell TransplantGlobeNewswireOXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the “Company”), a global, high-growth diagnostics company, today announces...
- 6y agoOXFDOxford Immunotec Announces Donation in Support of Coronavirus Testing Efforts to Help Differentiate Tuberculosis from the New China VirusGlobeNewswireOXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 23, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the “Company”), a global, high-growth diagnostics company, today announced...
- 6y agoOXFDOxford Immunotec to Present at the 38th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireOXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter...
- 6y agoOXFDOxford Immunotec to Participate in Two Investor ConferencesGlobeNewswireOXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter...
- 7y agoOXFDOxford Immunotec Schedules Third Quarter 2019 Earnings Release and Conference Call for November 5, 2019GlobeNewswireOXFORD, United Kingdom and MARLBOROUGH, Mass., Oct. 22, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced...
- 7y agoOXFDOxford Immunotec to Participate in Two Upcoming Investor ConferencesGlobeNewswireOXFORD, United Kingdom and MARLBOROUGH, Mass., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), or the Company, a global, high-growth diagnostics company, today announced...
- 8y agoOXFDOxford Immunotec Global PLC (OXFD) CEO Dr. Peter Wrighton-Smith on Q3 2018 Results - Earnings Call TranscriptEarnings Call Transcripts
- 10y agoOXFDOxford Immunotec Global PLC (OXFD) CEO Peter Wrighton-Smith on Q2 2016 Results - Earnings Call TranscriptEarnings Call Transcripts
- 10y agoOXFDOxford Immunotec Global's (OXFD) CEO Peter Wrighton-Smith on Q4 2015 Results - Earnings Call TranscriptEarnings Call Transcripts